AlphaQuest LLC Acquires 27,579 Shares of Dynavax Technologies Corporation $DVAX

AlphaQuest LLC grew its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 50.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 82,499 shares of the biopharmaceutical company’s stock after acquiring an additional 27,579 shares during the quarter. AlphaQuest LLC owned 0.07% of Dynavax Technologies worth $818,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. purchased a new position in Dynavax Technologies during the 1st quarter worth $312,000. GAMMA Investing LLC boosted its holdings in Dynavax Technologies by 88.4% during the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 3,627 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Dynavax Technologies during the 1st quarter worth $2,477,000. Woodline Partners LP boosted its holdings in Dynavax Technologies by 48.4% during the 1st quarter. Woodline Partners LP now owns 1,178,763 shares of the biopharmaceutical company’s stock worth $15,289,000 after acquiring an additional 384,288 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in Dynavax Technologies by 4.3% during the 2nd quarter. Exchange Traded Concepts LLC now owns 133,601 shares of the biopharmaceutical company’s stock worth $1,325,000 after acquiring an additional 5,523 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Dynavax Technologies

In related news, Director Scott Dunseth Myers purchased 3,800 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were purchased at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the completion of the transaction, the director directly owned 35,004 shares in the company, valued at approximately $378,743.28. This represents a 12.18% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 2.98% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on DVAX shares. JMP Securities reissued a “market outperform” rating and issued a $32.00 price target on shares of Dynavax Technologies in a report on Friday, August 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a report on Friday. Finally, Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Dynavax Technologies presently has a consensus rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Trading Up 1.9%

Shares of DVAX opened at $10.38 on Monday. The business’s 50-day moving average price is $10.02 and its 200-day moving average price is $10.32. Dynavax Technologies Corporation has a twelve month low of $9.20 and a twelve month high of $14.63. The stock has a market cap of $1.22 billion, a PE ratio of -22.57 and a beta of 1.13. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The firm had revenue of $95.44 million for the quarter, compared to analysts’ expectations of $87.55 million. On average, equities analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.